Protein dynamics, modifications and trafficking are all processes that can modulate protein activity. Accumulating evidence strongly suggests that many proteins have distinctive roles dependent on cellular location. Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) is a transforming growth factor-β (TGF-β) superfamily protein that has a role in cancer, obesity and inflammation. NAG-1 is synthesized and cleaved into a mature peptide, which is ultimately secreted into the extracellular matrix (ECM). In this study, we have found that full-length NAG-1 is expressed in not only the cytoplasm and ECM, but also in the nucleus. NAG-1 is dynamically moved to the nucleus, exported into cytoplasm and further transported into the ECM. We have also found that nuclear NAG-1 contributes to inhibition of the Smad pathway by interrupting the Smad complex. Overall, our study indicates that NAG-1 is localized in the nucleus and provides new evidence that NAG-1 controls transcriptional regulation in the Smad pathway.
INTRODUCTION
The study of genes altered by anticancer compounds has great value in regard to cancer chemoprevention and therapeutics. Building on this research, we identified the nonsteroidal antiinflammatory drug (NSAID)-activated gene-1 (NAG-1) as a divergent member of the transforming growth factor-β (TGF-β) superfamily.
1 NAG-1 has also been identified by other groups using a variety of different cloning strategies and has been called growth differentiation factor 15, 2 placental transformation growth factor-β, 3 macrophage inhibitory cytokine-1, 4 prostate-derived factor 5 and placental bone morphogenetic protein. 6 Research to date has demonstrated that NAG-1 is able to be induced not only by NSAIDs, 7 but also by chemopreventive dietary compounds [8] [9] [10] [11] [12] and peroxisome proliferator-activated receptor-γ (PPARγ) ligands. [13] [14] [15] [16] These compounds affect NAG-1 induction via the tumor-suppressor genes p53, early growth response-1 (EGR-1), and/or via the phosphatidylinositol 3 kinase/AKT/glycogen synthase kinase-3β pathway. 13, [17] [18] [19] Unlike the transcriptional regulation of NAG-1, the principal function, receptor and signaling pathway of NAG-1 remain uncertain, and the biological role of NAG-1 in tumorigenesis remains poorly understood and sometimes contradictory. For example, NAG-1 has a role in cancer development and progression, but various results show it acting as either a pro-tumorigenic or antitumorigenic protein. 20 NAG-1 also controls stress responses, bone formation, hematopoietic development and adipose tissue function, as well as contributing to cardiovascular diseases. [21] [22] [23] Our group has developed a transgenic mouse that ubiquitously overexpresses the human NAG-1 gene. 24 These mice are resistant to chemical-and genetic-induced cancers and have a decreased systemic inflammatory response. 21, 24, 25 Furthermore, the transgenic mice weigh less and have less fat, despite similar food intake as wild-type (WT) littermates, suggesting NAG-1 may act to alter metabolism as well. 24 Recently, we reported that NAG-1 modulates metabolic activity by increasing the expression of key thermogenic and lipolytic genes in adipose tissue. 26 That study suggested that NAG-1 is also a novel therapeutic target in preventing and treating obesity and insulin resistance.
NAG-1 is synthesized as a 308-amino-acid pro-NAG-1 monomer and then dimerizes by a specific disulfide linkage. The pro-NAG-1 dimer is then cleaved by furin-like proteases at an RXXR site, forming a 112-amino-acid C-terminal dimeric protein and propeptide. 20 This mature dimeric protein is secreted into the extracellular matrix (ECM), and can be detected in the blood of humans. Some evidence suggests the pro-NAG-1 dimer binds to the ECM and contributes to latent storage in the stroma, 27 but the fate and role of pro-NAG-1 is poorly understood. Experimental evidence clearly confirms the secreted mature dimer has biological activity; 26 however, the multiple forms of NAG-1 present in the cells, their interaction with the cellular system and their biological activity is unclear. Therefore, there is clearly a need for further study of the molecular mechanisms by which pro-NAG-1 contributes to NAG-1's biological activity.
A number of studies suggest that secreted proteins can localize in the nucleus and exhibit distinctive activity. 28, 29 For example, secreted proteins basic fibroblast growth factor and odontogenic ameloblast-associated protein are expressed in the nucleus and cytoplasm, as well as the ECM. 30 Thus, a secreted protein-like NAG-1 could also localize and alter molecular events within the nucleus. In this report, we tested this hypothesis and show the trans-localization of pro-NAG-1 into the nucleus followed by its exportation by chromosome region maintenance 1 (CRM1).
TGF-β is a strong epithelial-mesenchymal transition (EMT) inducer, and substantial studies established crucial roles of TGF-β-induced EMT in tumor progression. 31 EMT enhances cellular migration and invasion properties, as cell migration required loss of cell-cell contacts and acquisition of mesenchymal characteristics. 32 In addition, TGF-β regulates the expression and secretion of matrix metalloproteinase 2 (MMP2) and MMP9, and the modulations of the extracellular structure is required for tumor angiogenesis. Thus, TGF-β contributes to enabling tumor cells to invade normal tissues and metastasize to distant organs. Our results suggest that the cleavage of pro-NAG-1 to the mature form and its subsequent secretion is dependent on translocation into the nucleus. The pro-NAG-1 inside the nucleus altered gene expression and interfered with the TGF-β1-induced Smad signaling pathway, thereby altering cell migration. This is the first study demonstrating the critical importance of NAG-1 nuclear translocation in secretion of the mature dimer and the first report confirming a biological activity for pro-NAG-1 in the nucleus.
RESULTS
Full-length WT NAG-1 (pro-NAG-1) translocates to the nucleus As emerging evidence suggests that proteins exhibit distinctive activities based on cellular location, we decided to examine whether NAG-1 protein is located in different cellular regions. NAG-1 is first formed as pro-NAG-1 and then cleaved into a pro-peptide and a mature dimer form, which is then secreted into circulation. To investigate the cellular location of NAG-1 and the secretion events, we first used U2OS stable cell lines in which pro-NAG-1 is induced by treatment with tetracycline. 33 Only the pro-NAG-1 was present inside the cells with no mature form observed (Figure 1a) . Interestingly, nuclear/cytoplasmic fractionation of U2OS cells demonstrated that pro-NAG-1 was equally expressed in both the cytoplasm and the nucleus in U2OS cells (Figure 1b) . Lamin A/C and tubulin α were used as controls for nuclear and cytoplasmic fractions, respectively. To confirm our finding, we constructed expression vectors for green fluorescent protein (GFP)-and V5/His-tagged NAG-1 and conducted an immunofluorescence assay to observe subcellular localization of NAG-1 in U2OS cells transiently transfected with the NAG-1/GFP expression vector. NAG-1 signal (green) was observed in both the nucleus and the cytoplasm with a considerable signal in the endoplasmic reticulum (ER)/Golgi region (Figure 1c) . NAG-1 seemed to be localized in nucleolus; however, NAG-1 expression was not confined to nucleolus, as shown in a colocalization experiment with fibrillarin, a marker for nucleolus expression (Supplementary Figure S1a) . To define the location of NAG-1 in more detail, we performed subcellular fractionation, which separates cell components into soluble cytoplasmic extract, Figure 1 . NAG-1 expression observed in the nuclear fraction. (a) Western blot analysis of tetracycline-inducible U2OS cells. Cells grown in tetfree fetal bovine serum were treated with 2 μg/ml tetracycline for the indicated times. Actin antibody was used for the loading control. (b) Nuclear and cytoplasmic expression of NAG-1. Cytoplasm and nuclear fractions of inducible U2OS cells were isolated after stimulation with 2 μg/ml tetracycline for 24 h. Expression of NAG-1, lamin A/C (nuclear marker) and tubulin α (cytoplasmic marker) were analyzed by western blot. (c) U2OS cells transfected with GFP-tagged NAG-1 (WT) were fixed and analyzed by immunofluorescence with antibodies against GFP as described in the Materials and methods section. 4,6-Diamidino-2-phenylindole (DAPI) was used to stain the nuclei. Two independent fields are shown. (d) Tetracycline-induced U2OS (top panel) and WT U2OS cells transfected with NAG-1/V5/His expression vector (bottom panel) were subjected to subcellular fractionation, and western blot was performed. CE, cytoplasmic extract; ME, membrane extract; NE, nuclear extract; CB, chromatin-bound extract. Markers in each fraction are shown. Sp3 exhibits multiple bands, and a 78 kDa band is shown. (e) HCT-116 cells were treated with 10 μM of each compound for 24 h and subjected to western blot analysis. MCC-555 is a PPARγ ligand, whereas SS (sulindac sulfide) and TA (tolfenamic acid) are NSAIDs. DMSO was used for a vehicle. membrane extract, soluble nuclear extract and chromatin-bound protein extract. As shown in Figure 1d , pro-NAG-1 was expressed in both membrane extract and nuclear extract fractions. Cell lysates from tet-inducible system and WT U2OS cells transiently transfected with the pNAG-1/V5/His expression vector were separated into components. The phenomenon of finding pro-NAG-1 in nuclear fractions is observed both in the transient and stable NAG-1-expressing cells. Endogenous NAG-1 expression is induced by treatment with several anticancer compounds in HCT-116 human colorectal cancer cells. 34 As shown in Figure 1e , HCT-116 cells incubated with anticancer compounds for 24 h express endogenous pro-NAG-1 in nucleus, suggesting a rapid translocation into the nucleus. A confocal microscopy analysis supports our finding that NAG-1 is present in the nucleus (Supplementary Figure S1b) . Overall, pro-NAG-1 is surprisingly expressed in the nucleus in addition to the membrane fractions, including the vesicle and ER/Golgi apparatus.
NAG-1 may contain a non-canonical nuclear localization signal domain and is imported to the nucleus via the nuclear pore complex As NAG-1 does not contain the classical nuclear localization signal (NLS), two independent programs were used to search for the non-classical NLS. 35, 36 Both programs found one potential nonclassical NLS (aa 190-197) . Another potential NLS (aa 211-218) was selected by only one program. Subsequently, two deletion mutant clones (Δ190-197 and Δ211-218) from the NAG-1/V5/His expression vector were generated (Figure 2a ) and expressed in WT U2OS and HCT-116 cells. Nuclear/cytoplasmic localization showed that the expression level of the two NAG-1 mutants was higher in the cytoplasmic fraction than in the nucleus, in both cell types (Figure 2a ). These data are further confirmed by subcellular fractionation, indicating that Δ190-197 NAG-1 has less NAG-1 expression in the nuclear extraction (Supplementary Figure S2a) . Thus, these mutant NAG-1 proteins are still translocated into the nucleus but at a much lower amount, compared with WT NAG-1. These results were confirmed by immunofluorescence analysis with NAG-1/GFP construct, indicating that less signal intensity of mutant NAG-1-transfected cells was observed in the nucleus, compared with WT NAG-1-transfected cells (Figure 2b ). Thus, these two regions, aa 190-197 and aa 211-218, may contribute, at least in part, to translocation of NAG-1 protein from the cytoplasm to the nucleus. It has been reported that a protein can have multiple NLS that may function cooperatively to affect efficient nuclear transport. 37, 38 As two putative NLS sites exhibit a marginal effect on nuclear entry of NAG-1, serial deletion mutant clones were generated to address this issue. As shown in Figure 2c , none of clones resulted in a higher ratio of cytoplasmic NAG-1 to nuclear NAG-1. However, the expression of one NAG-1 mutant clone (Δ2-29 clone) interestingly resulted in predominant expression in the nucleus (Figure 2c ). To determine whether this translocation requires energy and/or the nuclear pore complex (NPC), an in vitro nuclear import assay was performed using NAG-1/GFP fusion proteins. Permeabilized cells lose their transport systems; therefore, cytosolic extract and the ATP/GTP-regenerating system were provided to investigate nuclear uptake of NAG-1/GFP. As shown in Figure 2d , NAG-1/GFP protein localized in the nucleus, whereas GFP protein alone did not. These results suggest that NAG-1/GFP does not enter the nucleus by a simple diffusion pathway because of the large size of the NAG-1/GFP protein (460 kDa), and that ATP is required to transport NAG-1 into the nucleus. In addition, inactivation of the NPC by wheat germ agglutinin (WGA) abolished NAG-1 movement to the nucleus. As the secreted NAG-1 cannot be absorbed by the cells (Supplementary Figure S2b) , only cytoplasmic NAG-1 is subjected to nuclear entry. Taken together, these results indicate that the nuclear entry of NAG-1 is energy dependent via the NPC, and those two sites (190) (191) (192) (193) (194) (195) (196) (197) and 211-218), in part, contribute to the nuclear entry of NAG-1.
NAG-1 has a canonical nuclear export signal (NES) mediated by CRM1 Next, we decided to further analyze the 2-29 region of NAG-1, as shown in Figure 2c , in terms of nuclear accumulation of NAG-1. We generated more deletion clones within this region and found that the Δ14-29 clone contains a domain to control predominantly nuclear accumulation of NAG-1 (Supplementary Figures S3a  and b) . We also generated a glycosylation site mutant clone (N70A) because it has been known that glycosylation sites may affect nuclear translocation of proteins. 39 This clone showed an expression pattern of NAG-1 similar to that of WT (Supplementary Figure S3a) . As shown in Figure 3a , the Δ14-29 clone exhibited higher expression of NAG-1 in the nucleus (lane 3 vs 7). As control, we transfected an R193A mutant clone that cannot be cleaved at the RXXR site, and wherein mature NAG-1 cannot be secreted. To elucidate if the Δ14-29 mutant clone altered secretion of the mature form, conditioned medium from the same batch used in Figure 3a was purified, and secreted mature NAG-1 was measured by western blot analysis. As expected, both pro-NAG-1 and mature NAG-1 ( Figure 3b , lane 2) were detected in pNAG-1/V5 transfected medium, whereas the R193A clone secreted only the pro-NAG-1 ( Figure 3b , lane 4). However, we could not detect Δ14-29 pro-NAG-1 nor mature NAG-1 in the culture medium ( Figure 3b , lane 3). These data indicate that the Δ14-29 region is necessary for exporting pro-NAG-1 protein to the cytoplasm from the nucleus and thus no mature NAG-1 is present in the media.
Our results also indicate a putative NES sequence in the Δ14-29 region. 36 Therefore, two mutants (ΔNES and mutNES) were generated to investigate whether the Δ14-29 region has a role in nuclear exportation of NAG-1 ( Figure 3c ). The expression pattern of NAG-1 in U2OS cells with a ΔNES or mutNES construct showed essentially nucleus expression with little to no cytoplasm expression in contrast with the WT NAG-1 control (Figure 3c and Supplementary S4a). Confirmation of nuclear expression was obtained with immunofluorescence of U2OS cells transfected with pNAG/ΔNES/V5 and pNAG/mutNES/V5 constructs ( Figure 3d ). CRM1 (also referred to as exportin1 or Xpo1) is a key protein in exporting a protein from the nucleus into the cytoplasm. 40 To determine whether CRM1 is involved in NAG-1 exportation, we added the CRM1 inhibitor leptomycin B (LMB) to the cells to see nuclear retention of NAG-1. The pro-NAG-1 nuclear distribution was increased in the cells treated with LMB in a dose-dependent manner ( Supplementary Figures  4b-d ). Smad4 was used as a control because it is regulated by CRM1 in exportation out of the nucleus. 41 Finally, we conducted an immunoprecipitation assay to determine whether pro-NAG-1 physically interacts with CRM1. As shown in Figure 3e , pro-NAG-1 was indeed immunoprecipitated with CRM1, suggesting that NAG-1 exportation to the cytoplasm is controlled by CRM1. There is a possibility that the 14-29 aa region of NAG-1 may have signal sequences for direct secretion to the extracellular region in addition to those for exportation from the nucleus. To address this possibility, we observed the level of NAG-1 secretion after LMB treatment. As expected, LMB treatment blocked NAG-1 secretion, suggesting that the 14-29 aa region is not only for exportation from the nucleus but also for secretion ( Figure 3f ). To further support the evidence that an NES exists in NAG-1, we used the interspecies heterokaryon assay (Supplementary S4e), the results of which suggested that NAG-1 shuttles between the nucleus and the cytoplasm, and LMB treatment blocks nucleocytoplasmic shuttling properties of NAG-1.
RNA-seq analysis suggests that NAG-1 inhibits the expression of TGF-β target genes To date, little is known about the NAG-1 receptor and its downstream pathways. Transcriptome sequencing (RNA-seq) is a promising tool in elucidating downstream effects and/or pathways. To study the effects and downstream pathways of NAG-1, we used comparative RNA-seq profiling of the transcriptomes using U2OS and tet-induced U2OS cells. RNA-seq results revealed 142 differentially expressed genes ( Figure 4a ). Nineteen of the 142 genes were previously reported to be a potential TGF-β target gene with regard to their relative abundance presented in the heat map ( Figure 4b ). Ingenuity network analysis was used to identify possible interactions with other genes differentially expressed in our data set, and suggested NAG-1 expression reduced the expression of several TGF-β1-related genes ( Figure 4c ). Although we did not treat the cells with TGF-β1 for RNAseq experiments, U2OS cells exhibited basal level of p-Samd2/3 without exogenous TGF-β1 treatment (Supplementary Figure S5) . We selected 10 out of 19 genes because they are well-known Smad target genes and confirmed their expression in the cells transfected with pNAG-1/His/V5 expression vector by quantitative reverse transcriptase-PCR (qRT-PCR; Figure 4d ). Except for HMGA1, the expression of NAG-1 inhibited the expression of these downstream targets of TGF-β1, suggesting pro-NAG-1 acts as an inhibitor of the TGF-β1 pathway. To examine further the effect of pro-NAG-1 on the TGF-β signaling pathway, two promoter reporters, p3TP-Luc and pPAI-800-Luc, were transfected with NAG-1 expression vector into U2OS and HEK293 cells, which are responsible for TGF-β treatment. NAG-1 expression diminished TGF-β1-mediated Smad activities (p3TP-Luc and pPAI-800-Luc; Figure 4e ). Thus, pro-NAG-1 expression inhibits the TGF-β1-mediated Smad signaling pathway at the transcriptional level.
Nuclear NAG-1 mitigates TGF-β signaling via interrupting Smads to DNA binding To address to what extent NAG-1 is relevant to endogenous Smad target genes, we treated the cells with TGF-β1 and measured the expression of the known TGF-β target genes SERPINE1, TIMP3 and LTBP1. Gene expression was suppressed in the presence of NAG-1 and further suppressed in the presence of ΔNES-NAG-1, which is in agreement with a higher level of nuclear pro-NAG-1 (Figure 5a ). In U2OS and MCF-10A cells (TGF-β-responding cells), WT NAG-1 and mutNES NAG-1 expression inhibited the Smad pathway, as assessed by Smad-binding element (SBE) reporter activity (Figure 5b) . Similar results were observed in MCF7 cells using p3TP and PAI-1 reporters (Supplementary Figure S6a) . Expression of the R193A mutant, which does not produce the mature NAG-1, also inhibited TGF-β-mediated Smad transcriptional activity (Supplementary Figure S6b) , supporting the hypothesis that pro-NAG-1, but not mature NAG-1, is involved in the inhibition of Smad signaling.
To further investigate how NAG-1 modulates the TGF-β1 response, we measured the level of phosphorylation of Smad2 in the presence of TGF-β1. WT U2OS cells were transfected with either empty or NAG-1 expression vector and then treated with TGF-β1. After 1 h, the media were aspirated and fresh media were added. The cells were then harvested in a time course for western blot analysis. Pro-NAG-1 did not affect Smad2 phosphorylation (Figure 5c ), suggesting that upon TGF-β1 stimulation, NAG-1 inhibits TGF-β1 signaling without inhibiting phosphorylation of Smad2. To examine if pro-NAG-1 affects the translocation of Smad2 to the nucleus and Smad2 degradation, the distribution of Smad2 was investigated. As shown in Figure 5d , Smad2 distribution was the same in both cytosol (lanes 1, 2 vs 3, 4) and the nucleus (lanes 6, 7 vs 8, 9), regardless of whether NAG-1 was present. Furthermore, this result was confirmed using A549 cells that were transfected with either LacZ or ΔNES NAG-1, and the distribution of Smad2 between cytosol and nucleus was examined (Supplementary Figure S6c) . Thus, pro-NAG-1 did not affect Smad2 translocation into the nucleus upon TGF-β1 stimulation or Smad2 degradation. We next explored whether the DNA-binding activity of Smad was diminished by NAG-1 expression. The DNA pull-down assay indicated that SBE-binding activity of the Smad complex The putative NES sequence in human NAG-1 is aligned with NAG-1 in other species, and also compared with the known NES sequences in Smad4, Hsc70 and PKI. Two mutant NAG-1 clones, ΔNES and mutNES, are shown. U2OS cells were transfected with the indicated vectors. Nuclear, N, and cytoplasmic, C, fractions were analyzed using the indicated antibodies as shown at bottom. (d) U2OS cells were transfected with WT, ΔNES or mutNES NAG-1-expressing vectors, and immunofluorescence assay was performed with antibodies against V5 (green) with 4,6-diamidino-2-phenylindole (DAPI) staining (blue). Scale bars, 10 μm. (e) Tet-inducible U2OS cells were treated with 2 μg/ml tetracycline for 24 h, and cell lysates were isolated with a modified RIPA buffer as described in the Materials and methods section. The cell lysates were incubated overnight with 2 μg CRM1 or normal immunoglobulin G antibodies, subjected to immunoprecipitation for 3 h, and then subjected to western blot analysis using NAG-1 or CRM1 antibodies. The whole-cell lysate (WCL) was loaded with 30 μg. (f) U2OS cells were transfected with pNAG-1/V5/His WT for 6 h, then 10 nM LMB added for 18 h. Conditioned media from the cells was subjected to western blot analysis.
was diminished when NAG-1 was expressed, implying that NAG-1 may interrupt Smad DNA-binding activity in the nuclear region (Figure 5e, Supplementary Figure S6d) . Furthermore, a ChIP assay showed that NAG-1 inhibits binding of Smad to the promoter region of TGF-β target genes (Figure 5f ). Taken together, these results suggest that nuclear pro-NAG-1 attenuates TGF-β-mediated Smad signaling through interruption of DNA-binding activity of the Smad complex upon TGF-β1 stimulation.
NAG-1 attenuates TGF-β-induced cell migration TGF-β1 is a cytokine that increases cell migration and invasion. 42 We next examined if NAG-1 expression altered TGF-β1-induced cell migration. As shown in Figure 6a , NAG-1 expression diminished cell migration into the scratched region in response to TGF-β1. In addition, a transwell migration assay showed less migration in the NAG-1-or mutNES-NAG-1-expressing cells in comparison with the empty vector-transfected cells (Figure 6b ). We used a threedimensional culture system to study invasion. Spheroids composed of empty vector-transfected cells exhibited spindle-like protrusions after TGF-β1 treatment; however, spheroids composed of WTexpressing or mutNES-expressing cells did not (Figure 6c ). NAG-1 also suppressed expression of snail1 and slug, which are markers for EMT induced by TGF-β1 (Supplementary Figure S7) . Overall, NAG-1 expression appeared to suppress EMT and cell invasion activity of TGF-β1 by inhibiting Smad DNA-binding activity.
DISCUSSION
Multiple cellular localizations of protein give rise to multiple functions or integrate signals from different locations to fulfill one biological outcome. 43, 44 NAG-1 is a secreted TGF-β superfamily member, and has a role as a cytokine to affect several biological activities through an unknown receptor. Although working on cellular NAG-1 movement, we discovered that NAG-1 is significantly expressed in the nucleus and affects transcriptional was transfected into U2OS cells and total RNAs isolated; then qRT-PCR was performed as described in the Materials and methods section. The data were normalized by the expression of the housekeeping ribosomal protein, large, P0 (RPLP0) mRNA, and further normalized to the level of the empty vector-transfected group, which was set at 1. (e) Two reporter genes, p3TP-Luc and pPAI-800-Luc (SERPINE1 promoter), were cotransfected with either empty vector or NAG-1-expressing vector into U2OS and HEK293 cells that exhibited an intact TGF-β signaling pathway. Transfected cells were treated with TGF-β1 (10 ng/ml for 24 h), and luciferase activity was measured. The graph shows mean values with ± s.d. from three replicates. *Po 0.05, compared with NAG-1-transfected cells.
regulation of the Smad complex. NAG-1 expression is altered by a variety of signals, such as those from cytokines (interleukin-1β, tumor necrosis factor-α, macrophage colony-stimulating factor), 4 radiation, 3 tissue injury, 45 anoxia 46 and many chemopreventive/ chemotherapeutic chemicals, 47 suggesting NAG-1 signaling may be important for maintaining cellular homeostasis. In addition, NAG-1 is a target gene of several transcription factors, such as p53, 3, 48 nuclear factor-κB, 49 Sp1 (ref. 1) and Egr-1. 13 However, downstream signaling pathways affected by NAG-1 remain to be discovered.
Although in vitro assays show different results, the results from NAG-1 overexpression in NAG-Tg mice and NAG-1 depletion in NAG-1 knockout mice consistently support the notion for antitumorigenic activity. 24, 25, 50 Some possible explanations for the contradictory activity of NAG-1 in vitro include: (1) NAG-1's different functions in the different cancer types, (2) an unidentified role of pro-NAG-1 in cells and (3) the contribution of NAG-1-binding proteins or receptors in different cells. In fact, there are many examples of other proteins having dual biological functions in different cancer types and microenvironments. For example, EGR-1 has been shown to be associated with pro-tumorigenic activity in prostate cancer, 51 whereas EGR-1 acts like a tumorsuppressor protein in other cancers. 52 15-Lipooxygenase-1 (LOX-1) is another example; LOX-1 acts as a tumor suppressor in colorectal cancer and a pro-tumorigenic protein in prostate cancer. 53, 54 Thus, the fact that NAG-1 shows dual functions in carcinogenesis is not surprising. Lack of knowledge of NAG-1's receptor and/or binding proteins is a large hurdle to studying its signaling pathway; however, a couple of reports have suggested that NAG-1 may be involved in TGF-β receptor-mediated signaling. 3, 55 Based on our data, we were surprised to find that NAG-1 expressed in the nucleus, and that nuclear NAG-1 inhibited the formation of the TGF-β1-induced Smad/DNA complex formation, thereby inhibiting expression of Smad target genes. This observation consistently occurred in other cells, and our data suggest that inhibition of the Smad pathway by the nuclear NAG-1 expression may provide a After treatment with TGF-β1 (2 ng/ml) for 1 h, the media were replaced with fresh media, and cell lysates were isolated at the indicated time points. Whole-cell lysates (30 μg) were subjected to western blot analysis using phosphor-Smad2, and Smad2 antibodies. (d) Tet-inducible U2OS cells were stimulated with TGF-β1 (2 ng/ml) for the indicated time points, and then cell lysates were subjected to nuclear and cytoplasmic fractionation followed by western blot with the indicated antibodies. Lamin A/C and tubulin α were used as nucleus and cytoplasm markers, respectively. (e) DNA pulldown and western blot with anti-Smad2/3 and anti-Smad4 antibodies. Cell lysates from either U2OS or U2OS-tet cells were incubated with SBE oligo DNA as described in the Materials and methods section. SBE-bound proteins were reduced in U2OS-tet compared with U2OS (left panel), and similar results were obtained using ectopic NAG-1 expression vectors into U2OS cells (right panel). (f) In vivo binding of Smad2/3 to the TIMP3 or Smad7 promoter in U2OS cells stimulated with TGF-β1 (2 ng/ml) using the ChIP assay. Inducible U2OS cells were stimulated by tetracycline for 24 h (left panel), and WT U2OS cells were transfected with either empty vector or NAG-1-expressing vector (right panel). The ChIP assay for endogenous smad2/3 indicates enhanced recruitment of Smad2/3 to the TIMP3 or Smad7 promoter region after simulation with TGF-β1 for 3 h and decreased occupancy on these promoter regions by NAG-1 expression. new avenue to support NAG-1's role in antitumorigenesis. However, there is a dichotomy view that NAG-1 could positively affect to tumor development in where TGF-β exerts as a tumorsuppressor protein because TGF-β signaling is a complex web that target genes and biological consequences of TGF-β could be dictated by contextual determinants such as signal transduction, transcription and epigenetic status. 42 Our results also suggest that NAG-1 could translocate into the nucleus through an active transport system ( Figure 2d) ; however, we have yet to define the precise mechanisms involved in its nuclear importation. It is likely that multiple pathways or a novel pathway may affect NAG-1 movement to the nucleus because two potential mutations partially affected NAG-1 importation (Figures  2a and b) . We also made a double mutation clone at Δ190-197 and Δ211-218, and found that this clone exhibited a similar pattern as the single mutation clone (data not shown). As no canonical NLS signals were found in the NAG-1 full-length peptide sequences, NAG-1 may have a unique mechanism that is able to translocate it into the nucleus. NAG-1 has two putative SUMOylation sites at C-terminal region (http://www.abgent.com/tools). SUMOylation could also exert for nuclear localization of NAG-1. 56 Thus, it is possible that SUMOylation of NAG-1 may affect nuclear translocation when the two NLS sites in NAG-1 are disrupted. The TGF-β superfamily member bone morphogenetic protein 2 has been observed in a truncated form in the nucleus; 57 however, this study is the first report that a full-length TGF-β superfamily protein is expressed in the nucleus and has a role in transcription. Nuclear importation of NAG-1 requires energy and carrier proteins. GFP by itself was not able to enter nuclei ( Figure 2d) ; however, NAG-1/GFP was imported into the nucleus as examined by an in vitro import assay. Depleting the energy generation system and NPC inhibitor WGA treatment in the permeabilized cells reduced nuclear uptake of NAG-1, suggesting that NAG-1 nuclear entry occurs through the NPC in an energy-dependent manner. Given that NAG-1 lacks a classical NLS region and requires the NPC for translocation, nuclear localization of NAG-1 likely requires interaction with a partner that contains the NLS domain. 58 Indeed, nuclear importation of protein can be mediated by multiple transport receptors, 37, 38 or a protein containing armadillo repeats can directly interact with a component of nuclear pore proteins. 59 Thus, it is likely that a portion of NAG-1 is exposed to the cytoplasm, whereas another portion of NAG-1 is embedded in ER/ Golgi for being recognized by a transporter, as seen in epidermal growth factor receptor nuclear importation. 60 Although we have not ruled out these possibilities, our data indicate that two sites (190) (191) (192) (193) (194) (195) (196) (197) and 211-218) have a role, at least in part, in importing NAG-1 to the nucleus. Further experiments are necessary to define the molecular mechanism of nuclear transport and specifically, the exact component of import machinery for NAG-1.
In comparison with the importation mechanism of NAG-1, we were able to investigate in greater detail NAG-1 exportation to the cytoplasm. NAG-1 export was mediated by an LMB-sensitive, CRM1-dependent pathway, which requires a functional domain to be recognized by CRM1. Sequence analysis showed that the canonical, leucine-rich NES was present within the N-terminal region of NAG-1. If this site were deleted or mutated, then NAG-1 was retained in the nucleus of the cells. We also observed that NAG-1 physically bound to CRM1; however, we cannot exclude the possibility that other nuclear proteins that supply NES may help NAG-1 exportation. Interestingly, we could not find secreted mature NAG-1 in the culture medium when NAG-1 was retained in the nucleus. It is likely that one of the secretion pathways of NAG-1 must pass through the nucleus before processing to the mature form. Vesicles are required for NAG-1 secretion, and the vesicle containing NAG-1 may form at the nuclear membrane; therefore, an NES sequence may have a pivotal role in vesicle formation. Indeed, our results show that NAG-1 is localized in the ER/Golgi region in the cytoplasm, not as a soluble cytosolic fraction ( Figure 1d ) and that this localization is dependent upon sequences in the N-terminal domain, a region that contains an NES sequence (Figure 3c) . Notably, there is a possibility that antitumorigenic activity of NAG-1 may occur with nuclear NAG-1, whereas secreted mature NAG-1 protein may possess pro-tumorigenic activity. This is supported by previous reports indicating that recombinant NAG-1 increases kinase pathways in some cancer cells. 61 Although further mechanistic studies are required to define the exact biological activity of nuclear NAG-1 and secreted mature NAG-1, our data clearly show that nuclear NAG-1 causes inhibition of cell migration and invasion mediated by TGF-β1, as assessed by experiments with mutant clones. Based on our data and that in the literature, it is postulated that more nuclear NAG-1 will be expressed in cells that need antitumorigenic status, whereas more secreted NAG-1 will be expressed in protumorigenic status.
The biological role of NAG-1 nuclear-cytoplasmic shuttling remains to be established. In this study, we found that nuclear NAG-1 could control the strength of TGF-β1-mediated Smad signaling. It remains to be clarified how nuclear NAG-1 modulates the DNA-binding capacity of the Smad complex, although it has been known that various factors and cellular context attenuate Smad-mediated transcription. One possible way is that NAG-1 may bind directly to DNA (SBE) to compete with Smad, although no DNA-binding motif has been identified in the NAG-1 sequence. To test this hypothesis, we used ChIP-seq to see if any DNA fragments were pulled down with NAG-1. It is not likely that NAG-1 directly binds to conserved SBE, as we have not identified any genes related to the SBE-containing promoter. Another possibility is that NAG-1 may bind to Smad2, thereby inhibiting Smad-binding activity. However, we could not find any direct physical interaction between Samd2/3/4 and NAG-1 (Supplementary Figure S8) . Our data rather imply that NAG-1 somehow interrupts the Smad complex in the nucleus by an unknown mechanism(s). Smad proteins may need an additional transcription factor or co-factor to strongly occupy their target DNA. 62, 63 Thus, NAG-1 may disrupt the formation of the Smad complex upon TGF-β1 stimulation, or NAG-1 may somehow facilitate ADP-ribosylation, which dissociates the Smad complex from DNA, leading to attenuation of a Smad-specific gene response. 64 Another possible explanation is that NAG-1 may affect phosphorylation sites in the hinge region by nuclear protein CDK8/9. 65 This facilitates Smad protein binding to another DNA-binding co-factor, which is required for proper transcription of TGF-β target genes. Thus, it is likely that many pathways are additively involved in interrupting the Smad complex by NAG-1 expression.
Our data show that all cells tested tended to express NAG-1 in varying amounts in both the cytoplasm and nucleus (Figure 3a) . This provides a model that could demonstrate strategies for therapeutic intervention in disease states in which 'inappropriate' localization of protein is believed to contribute to disease development. 66 It remains to be elucidated whether more transformed tumor cells activate mechanisms that allow increased nuclear import or decreased nuclear export of NAG-1. We are currently developing an antibody that recognizes the N-terminal region of NAG-1 to examine NAG-1 expression in the nucleus of human tissue samples and to determine whether more nuclear staining of NAG-1 is associated with a better prognosis in cancer patients.
In summary, our data indicate that the pro-NAG-1 was expressed in the nucleus and appears to have a role in transcriptional regulation by disturbing the Smad complex. In addition, nuclear retention resulted in an absence of secreted mature NAG-1. The schematic diagram in Figure 6d represents the proposed model of the molecular mechanism of nuclearcytoplasmic NAG-1 shuttling through active transport and nuclear NAG-1, attenuating TGF-β signaling through interruption of DNA binding of the Smad complex upon TGF-β stimulation. In addition, the novel role of NAG-1 in the nucleus may help lead to the development of new drugs that facilitate the retention of NAG-1 in the nucleus or to the development of novel diagnostic tools for assessing cancer progression.
MATERIALS AND METHODS
Cell culture and reagents U2OS and HCT-116 were cultured in McCoy's 5A supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) and 1% penicillin/streptomycin (Lonza, Walkersville, MD, USA). HEK293 cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 1% penicillin/streptomycin. The NAG-1 tetracycline-inducible U2OS cell line has been described previously. 33 All cultured cells were maintained at 37°C in humid conditions with 5% CO 2 . The following antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA): anti-V5 (sc-271944), anti-CRM1 (sc-5595), anti-tubulin α (sc-8035), anti-lamin A/C (sc-6215), anti-histone H1 (sc-10806), anti-β-actin (sc-47778) and anti-GFP (sc-9996). Anti-Smad2 (5339), anti-phosphor-smad2 (3108), anti-smad2/3 (8685), anti-phosphor-smad2/3 (8828), antismad4 (9515), anti-snail (3879), anti-slug (9585), anti-hsp90 (4877) and anti-calnexin (2679) were purchased from Cell Signaling (Danvers, MA, USA). Recombinant human TGF-β1 (8915) was also purchased from Cell Signaling. CRM1 inhibitor (LMB, L-6100) was from LC Laboratories (Woburn, MA, USA).
DNA constructs and transfection. Full-length NAG-1 PCR product amplified from pcDNA3/NAG-1 (ref. 34) was sub-cloned into pcDNA3.1/V5/His-TOPO vector (Invitrogen, Carlsbad, CA, USA) and pcDNA3.1/CT-GFP-TOPO vector (Invitrogen) to generate the V5/His-and GFP-tagged clones, respectively. All mutant constructs were generated from pNAG-1-V5/His or pNAG-1-GFP using the QuickChange II site-directed Mutagenesis Kit (Stratagene, Santa Clara, CA, USA). PCR primer sequences are described in Supplementary Table 1 , and all DNA constructs used were verified by DNA sequencing. Transient transfections were carried out using either PolyJet (SignaGen, Gaithersburg, MD, USA) or TransIT-2020 transfection reagent (Mirus Bio, Madison, WI, USA) according to the manufacturer's protocol.
Luciferase assay. Cells were seeded on a 12-well plated at a density of 1.0 × 10 5 cells per well. TGF-β1-inducible reporter constructs p3TP-luc, pPAI-800-luc (SERPINE1 promoter) and pSBE4-luc were each co-transfected with pRL-null vector. After 24-h transfection, cells were stimulated with TGF-β1 for 24 h in serumfree conditions, and then were harvested in 1 × passive lysis buffer (Promega, Madison, WI, USA). Luciferase activity was examined using a DualGlo Luciferase Assay Kit (Promega), and data were normalized by pRL-null luciferase activity. Western blot and immunoprecipitation. For western blot, reduced protein samples lysed by RIPA buffer were separated on 8% or 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, and transferred to nitrocellulose membranes (Osmonics, Minnetonka, MN, USA). The membranes were incubated with a specific primary antibody in Tris-buffered saline (TBS) containing 0.05% Tween 20 (TSB-T) and 5% nonfat dry milk at 4°C overnight. After three washes with TBS-T, the blots were incubated with horseradish peroxidase-conjugated immunoglobulin G for 1 h at room temperature, visualized using detection reagent (Thermo Scientific), and quantified by Scion Image Software (Scion Corp., Frederick, MD, USA). To conduct immunoprecipitation analysis, 1 mg of cell extract lysed by modified RIPA buffer (25 mM Tris-Cl pH 7.4, 150 mM NaCl, 1% NP-40 and 5% glycerol) was incubated with 2 μg primary antibody for 2 h at 4°C on a rotating platform, followed by adding protein A/G PLUS-agarose (Santa Cruz Biotechnology) overnight. Immunoprecipitation was collected by centrifuge at 1000 × g for 3 min. After washing five times with modified RIPA buffer, the pellets were resuspended with 50 μl 2XSDS-PAGE sample loading buffer and heated at 95°C for 5 min. Western blot analysis was conducted as described above using 20 μl of the immunoprecipitated samples.
In vitro nuclear import assay. HCT-116 cells were plated on glass coverslips 24 h before use. The cells were rinsed three times with transport buffer (TB; 20 mM HEPES, pH 7.3, 110 mM potassium acetate, 2 mM magnesium acetate), and permeabilized for 5 min with complete TB containing 1 mM EGTA, 2 mM DTT, 1 mM PMSF, protease inhibitor cocktail and 30 μg/ml digitonin on ice. After two washes with TB, the permeabilized cells were incubated in complete TB with HCT-116 cytosol extract, the appropriate GFPtagged NAG-1 expressed in in vitro TNT Quick Coupled Transcription/Translation Systems (Promega), and an ATP regeneration system (0.5 mM ATP and GTP, 5 mM creatine phosphate and 50 μg/ml creatine kinase). Assays in the absence of an energy-regenerating system were conducted with TB without the ATP regeneration system. For WGA treatments, permeabilized cells were incubated in the presence of 0.05 mg/ml WGA in TB for 15 min before the import reaction. After the import assay, cells were fixed with 4% paraformaldehyde, and fluorescent proteins were analyzed by immunofluorescence assay.
Library preparation and next-generation sequencing. Inducible U2OS cells were grown in the presence or absence of tetracycline (2 μg/ml) for 2 days. Total RNAs were isolated using E.Z.N.A Total RNA Kit (Omega Bio-Tek, Norcross, GA, USA) following the manufacturer's protocol. An Illumina TruSeq RNA kit (V2; San Diego, CA, USA) was used for library preparation of mRNA-Seq according to the vendor's instruction. Briefly, (poly A+) mRNAs were purified from 1 μg total RNA using poly-T magnetic beads. Messenger RNAs were fragmented to desired lengths by incubating at an elevated temperature (94°C) for 8 min in the presence of metal ions. The RNAs were used as templates for the syntheses of the first-and second-strand complementary DNAs, which were subsequently subjected to end repair, A-tailing at 3' ends, adapter ligation, and 15-cycle PCR amplifications. During PCR, individual barcodes were incorporated into respective samples to enable sample pooling in subsequent DNA sequencing. Paired-end 100-cycle sequencing of the prepared RNA-Seq libraries were performed on an Illumina HiSeq 2500, following standard protocols of the manufacturer.
Next-generation sequencing data analysis. Sequence reads were processed using the Tuxedo suite (Baltimore, MD, USA). 67 Briefly, fastq files were aligned to the UCSC human reference genome (hg19) using the TopHat v.2.0.6 software program (Johns Hopkins University, Baltimore, MD, USA). The aligned reads were then assembled by Cufflinks v.2.0.2 (http://cole-trapnell-lab.github.io/ cufflinks/) to produce individual transcripts, followed by Cuffmerge to integrate the reference human genome annotation (GTF transcription annotations from Illumina iGenomes). The output files were then passed onto the Cuffdiff program to create differential expression results.
Real-time qRT-PCR. Total RNA was isolated using an E.Z.N.A Total RNA Kit (Omega Bio-Tek) according to the manufacturer's protocol. Complementary DNA was made from 1 μg isolated RNA using a Verso cDNA synthesis kit (Thermo Scientific) according to the manufacturer's protocol. PCR was carried out using iTaq Universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). Primers used for qRT-PCR are provided in Supplementary  Table 3 . Relative quantities of mRNAs were calculated using the ΔΔC t method and normalized using human Ribosomal Protein, Large, P0 (RPLP0) as an endogenous control.
Scratch and transwell migration assay. For the scratch migration assay, inducible U2OS cells were plated onto a six-well plate and cultured to near (490%) confluence. Cells were serum starved for 24 h in the presence or absence of 2 μg/ml tetracycline, and the monolayer was scratched with a sterile 10 μl-pipette tip. Then serum-free media containing 10 ng/ml of TGF-β1 was added for 24 h. Phase-contrast images were acquired at 0 and 24 h after the gaps were created. The cells migrated into the gaps were counted from three different gap regions. For the transwell migration assay, transfected U2OS cells were resuspended in serum-free medium, and the cell suspension (4 × 10 4 cells) was added to the upper transwell chamber (pore size of 8 μM; Costar; Corning, Corning, NY, USA). Media containing 0.1% serum and TGF-β1 was added to the bottom wells of the chambers. Cells were incubated for 18 h at 37°C, fixed with 4% paraformaldehyde, and permeabilized by 100% methanol. Cells were then stained with 0.5% crystal violet dissolved in 20% methanol at room temperature for 15 min. Cells that had not migrated after 18 h were removed from the upper face of the filters using cotton swabs. Migrated cells were counted under a light microscope. Images of three different fields were taken for each membrane.
Three-dimensional spheroid invasion assay. A 96-well threedimensional spheroid BME cell invasion assay kit (Trevigen, Gaithersburg, MD, USA) was used according to the manufacturer's protocol with minor modification. Briefly, 2000 cells were resuspended in serum-free media containing spheroid formation ECM. The cells were added to a 96-well ultralow attachment round bottom plate, and then incubated for 1 day to allow cells to assemble into compact spheroids. Invasion matrix was added to each well, and then the cells were incubated for 1 h before adding serum-free media containing 10 ng/ml TGF-β1. The plate was incubated for 2 days, and spheroids were photographed at × 8 magnification.
DNA pull-down assay. Tetracycline-treated or non-tetracyclinetreated inducible U2OS cells grown on a 10-cm dish were stimulated with or without 5 ng/ml of TGF-β1 for 2 h. Whole-cell lysates were prepared in lysis buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM DTT, 0.1% NP-40 and 10% glycerol). Lysates were centrifuged at 4°C for 15 min at high speed. Cell lysate (500 μg) was incubated with 5 μg poly(dI-dC) and 1 μg biotinylated SBE oligonucleotides containing SBEs at 4°C for 16 h. DNA-bound proteins were collected with streptavidin beads (G-Biosciences, St Louis, MO, USA) for 2 h. Beads were collected by centrifugation for 30 s at 3000 g and washed four times with lysis buffer. Then, 2Xsample buffer (50 μl) was added to the beads and boiled for 5 min, followed by western blotting. The SBE probe sequence for DNA pull-down was Biotine-5′-TCGATAGCCA GACAGGTAGCCAGACAGGTAGCCAGACAGGTAGCCAGACAGG-3′. 68 Chromatin immunoprecipitation. For the chromatin immunoprecipitation assay, a MAGnify chromatin immunoprecipitation system (Invitrogen) was used according to the manufacturer's protocol. Briefly, cells were grown to 70~80% confluence in a 150-mm dish. The cells were cross-linked with 1% formaldehyde for 10 min at room temperature. Crosslinking reactions were quenched with 0.125 M glycine for 5 min at room temperature. The cells were scraped and moved to a 1.5-ml tube, then sonicated for eight cycles of 15-s on/1-min off. Sheared chromatin was incubated with either Smad2/3 antibody or normal immunoglobulin G conjugated with beads for 2 h at 4°C. Chromatinbound DNA was reverse cross-linked and DNA was purified. Purified DNA was subjected to qRT-PCR using the following primer pairs: TIMP3 promoter region, forward 5′-GCAAACAGCAGATGGCTTCC-3′ and reverse 5′-CCTTGACTGTGCTT GGTGGA-3′; SMAD7 promoter region, forward 5′-TTCTGGGAGCTT CTCTGCCC-3′ and reverse 5′-GCTCCGGCCTCGTCAC-3′.
Interspecies heterokaryon assay. The human U2OS cells grown in glass bottom dishes were transiently transfected with the pNAG-1/V5/His expression vector. At 24 h after transfection, the U2OS cells were washed with PBS twice, and then an equal number of murine NIH3T3 cells were seeded onto the same glass bottom dishes. After 6-h incubation, cycloheximide (100 μg/ml) and 10 nM LMB were added to inhibit protein synthesis and nuclear export of a protein. The co-cultured cells were washed twice with PBS after 2 h and were added with polyethylene glycol MW 8000 (PEG) 50% (w/v) in PBS for 2 min to allow cell fusion, followed by washing twice with serum-free medium containing cycloheximide. The cells were then incubated with complete media (plus cycloheximide along with LMB) for 1 h. After fixation in 4% paraformaldehyde, the cells were counterstained with Hoechst 33258 to distinguish human U2OS nuclei from those of murine NIH3T3 cells.
Statistical analysis. Statistical analysis was performed with the Student's unpaired t-test. Results were considered statistically significance at *P o0.05, **P o 0.01 and ***P o 0.001.
